Related Experiment Video
Updated: Jan 8, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Metastatic lung pleomorphic giant cell carcinoma treated with multimodality systemic anti-cancer treatment, a
Aladdin Kanbour1, Afnan Alnajjar1, Mohannad N AbuHaweeleh2
1National Centre for Cancer Care and Research, Medical Oncology, Hamad Medical Corporation, Doha, Qatar.
Introduction:
Pleomorphic giant cell carcinoma (PGCC) of the lung is a rare and aggressive subtype of non-small cell lung cancer with limited therapeutic options. We present a case of a 50-year-old male with stage IV, PD-L1-negative PGCC managed through a sequential multimodal treatment approach.
Case Presentation:
A 50 year old gentleman, known to be a heavy smoker, presented with metastatic disease involving the lungs, bone, and lymph nodes. He received dual immunotherapy with Nivolumab and Ipilimumab, achieving a partial response before progression. Subsequent MAID chemotherapy provided transient disease control, followed by Carboplatin-Paclitaxel, which yielded a more durable response. With additional radiotherapy for brain metastases, the patient achieved an overall survival of 30 months.
Conclusion:
This case underscores the rarity and therapeutic complexity of metastatic PGCC and highlights the potential survival benefit of an adaptive, multidisciplinary treatment strategy integrating immunotherapy, chemotherapy, and targeted radiotherapy.
